Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial

HIV Vaccine Trials Network (HVTN) 505 was a phase 2b efficacy trial of a DNA/recombinant adenovirus 5 (rAd5) HIV vaccine regimen. Although the trial was stopped early for lack of overall efficacy, later correlates of risk and sieve analyses generated the hypothesis that the DNA/rAd5 vaccine regimen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virol
Autors principals: Li, Shuying S., Gilbert, Peter B., Carpp, Lindsay N., Pyo, Chul-Woo, Janes, Holly, Fong, Youyi, Shen, Xiaoying, Neidich, Scott D., Goodman, Derrick, deCamp, Allan, Cohen, Kristen W., Ferrari, Guido, Hammer, Scott M., Sobieszczyk, Magdalena E., Mulligan, Mark J., Buchbinder, Susan P., Keefer, Michael C., DeJesus, Edwin, Novak, Richard M., Frank, Ian, McElrath, M. Juliana, Tomaras, Georgia D., Geraghty, Daniel E., Peng, Xinxia
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6803257/
https://ncbi.nlm.nih.gov/pubmed/31434737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02041-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars